Janel R Long-Boyle1, Rada Savic, Shirley Yan, Imke Bartelink, Lisa Musick, Deborah French, Jason Law, Biljana Horn, Morton J Cowan, Christopher C Dvorak. 1. Departments of *Clinical Pharmacy, and †Bioengineering and Therapeutics, University of California San Francisco; ‡Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY; Departments of §Pharmacy, UCSF Benioff Children's Hospital, and ¶Laboratory Medicine, UCSF Medical Center, University of California San Francisco; ‖Department of Pediatrics, Floating Hospital for Children, Tufts University, Boston, MA; and **Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco.
Abstract
BACKGROUND: Population pharmacokinetic (PK) studies of busulfan in children have shown that individualized model-based algorithms provide improved targeted busulfan therapy when compared with conventional dose guidelines. The adoption of population PK models into routine clinical practice has been hampered by the tendency of pharmacologists to develop complex models too impractical for clinicians to use. The authors aimed to develop a population PK model for busulfan in children that can reliably achieve therapeutic exposure (concentration at steady state) and implement a simple model-based tool for the initial dosing of busulfan in children undergoing hematopoietic cell transplantation. PATIENTS AND METHODS: Model development was conducted using retrospective data available in 90 pediatric and young adult patients who had undergone hematopoietic cell transplantation with busulfan conditioning. Busulfan drug levels and potential covariates influencing drug exposure were analyzed using the nonlinear mixed effects modeling software, NONMEM. The final population PK model was implemented into a clinician-friendly Microsoft Excel-based tool and used to recommend initial doses of busulfan in a group of 21 pediatric patients prospectively dosed based on the population PK model. RESULTS: Modeling of busulfan time-concentration data indicates that busulfan clearance displays nonlinearity in children, decreasing up to approximately 20% between the concentrations of 250-2000 ng/mL. Important patient-specific covariates found to significantly impact busulfan clearance were actual body weight and age. The percentage of individuals achieving a therapeutic concentration at steady state was significantly higher in subjects receiving initial doses based on the population PK model (81%) than in historical controls dosed on conventional guidelines (52%) (P = 0.02). CONCLUSIONS: When compared with the conventional dosing guidelines, the model-based algorithm demonstrates significant improvement for providing targeted busulfan therapy in children and young adults.
BACKGROUND: Population pharmacokinetic (PK) studies of busulfan in children have shown that individualized model-based algorithms provide improved targeted busulfan therapy when compared with conventional dose guidelines. The adoption of population PK models into routine clinical practice has been hampered by the tendency of pharmacologists to develop complex models too impractical for clinicians to use. The authors aimed to develop a population PK model for busulfan in children that can reliably achieve therapeutic exposure (concentration at steady state) and implement a simple model-based tool for the initial dosing of busulfan in children undergoing hematopoietic cell transplantation. PATIENTS AND METHODS: Model development was conducted using retrospective data available in 90 pediatric and young adult patients who had undergone hematopoietic cell transplantation with busulfan conditioning. Busulfan drug levels and potential covariates influencing drug exposure were analyzed using the nonlinear mixed effects modeling software, NONMEM. The final population PK model was implemented into a clinician-friendly Microsoft Excel-based tool and used to recommend initial doses of busulfan in a group of 21 pediatric patients prospectively dosed based on the population PK model. RESULTS: Modeling of busulfan time-concentration data indicates that busulfan clearance displays nonlinearity in children, decreasing up to approximately 20% between the concentrations of 250-2000 ng/mL. Important patient-specific covariates found to significantly impact busulfan clearance were actual body weight and age. The percentage of individuals achieving a therapeutic concentration at steady state was significantly higher in subjects receiving initial doses based on the population PK model (81%) than in historical controls dosed on conventional guidelines (52%) (P = 0.02). CONCLUSIONS: When compared with the conventional dosing guidelines, the model-based algorithm demonstrates significant improvement for providing targeted busulfan therapy in children and young adults.
Authors: N Bleyzac; G Souillet; P Magron; A Janoly; P Martin; Y Bertrand; C Galambrun; Q Dai; P Maire; R W Jelliffe; G Aulagner Journal: Bone Marrow Transplant Date: 2001-10 Impact factor: 5.483
Authors: A M Bolinger; A B Zangwill; J T Slattery; L J Risler; D H Sultan; D V Glidden; D Norstad; M J Cowan Journal: Bone Marrow Transplant Date: 2001-12 Impact factor: 5.483
Authors: Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman Journal: N Engl J Med Date: 2003-09-18 Impact factor: 91.245
Authors: J S McCune; T Gooley; J P Gibbs; J E Sanders; E W Petersdorf; F R Appelbaum; C Anasetti; L Risler; D Sultan; J T Slattery Journal: Bone Marrow Transplant Date: 2002-08 Impact factor: 5.483
Authors: Celeste Lindley; Thomas Shea; Jeannine McCune; Stacy Shord; Jodi Decker; Donald Harvey; William P Petros; Don Garbriel; Jonathan Serody; Suzanne Kirby; Joseph Wiley Journal: Anticancer Drugs Date: 2004-06 Impact factor: 2.248
Authors: Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan Journal: Biol Blood Marrow Transplant Date: 2017-01-06 Impact factor: 5.742
Authors: Imke H Bartelink; Arief Lalmohamed; Elisabeth M L van Reij; Christopher C Dvorak; Rada M Savic; Juliette Zwaveling; Robbert G M Bredius; Antoine C G Egberts; Marc Bierings; Morris Kletzel; Peter J Shaw; Christa E Nath; George Hempel; Marc Ansari; Maja Krajinovic; Yves Théorêt; Michel Duval; Ron J Keizer; Henrique Bittencourt; Moustapha Hassan; Tayfun Güngör; Robert F Wynn; Paul Veys; Geoff D E Cuvelier; Sarah Marktel; Robert Chiesa; Morton J Cowan; Mary A Slatter; Melisa K Stricherz; Cathryn Jennissen; Janel R Long-Boyle; Jaap Jan Boelens Journal: Lancet Haematol Date: 2016-10-13 Impact factor: 18.959
Authors: Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar Journal: J Clin Pharmacol Date: 2017-12-14 Impact factor: 3.126
Authors: Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; William T Shearer; Lauri M Burroughs; Troy R Torgerson; Hélène Decaluwe; Elie Haddad Journal: J Allergy Clin Immunol Date: 2016-04-22 Impact factor: 10.793
Authors: George S Amatuni; Robert J Currier; Joseph A Church; Tracey Bishop; Elena Grimbacher; Alan Anh-Chuong Nguyen; Rajni Agarwal-Hashmi; Constantino P Aznar; Manish J Butte; Morton J Cowan; Morna J Dorsey; Christopher C Dvorak; Neena Kapoor; Donald B Kohn; M Louise Markert; Theodore B Moore; Stanley J Naides; Stanley Sciortino; Lisa Feuchtbaum; Rasoul A Koupaei; Jennifer M Puck Journal: Pediatrics Date: 2019-02 Impact factor: 7.124